Project Grant R21AG095389
- This three-year Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund $2,136,033 in research under the Aging Research program (CFDA 93.866). The grant recipient, Case Western Reserve University in partnership with University Hospitals of Cleveland, will investigate the role of the CHCHD6 protein in Alzheimer's disease pathology and potential therapeutic interventions. Specifically, the researchers will study the causes and consequences...
- This Project Grant award of $1,592,854.00 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports research to understand the role of the tau protein in the development of Alzheimer's disease and related dementias. The central hypothesis is that pathogenic forms of tau represent a misregulation of tau's normal biological function as a scaffold for regulating signaling pathways. The research aims to define the effects of tau post-translational...
- This federal Project Grant award, titled "Mapping Proteomic Changes of Tauopathy in Human Neurons", is funded by the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $717,709.00 and will be completed by March 31, 2030. The award is held by Weill Medical College of Cornell University and aims to use advanced proteomic and transcriptomic approaches to discover cellular mechanisms underlying the propagation of misfolded tau protein aggregates in human neurons,...
- This $130,302 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research at New York University School of Medicine to investigate the selective vulnerability of basal forebrain cholinergic neurons (BFCNs) to tau pathology in Alzheimer's disease (AD). The key products and services to be delivered include: Investigating the biochemical underpinnings and functional alterations of BFCNs with pathological tau accumulation using human induced...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,156,262.00 to Case Western Reserve University's Office of Research Administration Division (doing business as University Hospitals of Cleveland) to conduct research on the role of N6-methyladenosine (m6A) RNA modification dysregulation in the pathogenesis of Alzheimer's disease. The research aims to determine how reduced expression of the m6A methyltransferase enzyme METTL3...
- This Project Grant award of $161,000.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research conducted by Case Western Reserve University to investigate the role of RNA N6-methyladenosine (m6A) modification in tau mRNA metabolism and tauopathy, a group of neurodegenerative diseases characterized by abnormal tau protein accumulation. The project aims to determine the effect of reduced m6A methyltransferase METTL14 expression on tau mRNA methylation,...
- This federal Project Grant award of $431,750.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research at Rutgers, The State University to investigate the role of mitochondrial deficits in tauopathy-linked autophagy defects for Alzheimer's disease. The research aims to better understand the pathogenic mechanisms of tau protein, a key driver of neurodegeneration in Alzheimer's. The project will explore how early mitochondrial deficits, specifically reduced...
- This $165,348 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the cellular and molecular mechanisms underlying neurotoxicity and cognitive deficits caused by hyperphosphorylated tau protein, a hallmark of Alzheimer's disease. The grant recipient, the Rector & Visitors of the University of Virginia, will use a combination of transcriptomic profiling and neurophysiology approaches to characterize the effects of...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports comprehensive proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The $784,596 grant aims to develop a state-of-the-art proteogenomic pipeline to globally profile disease-associated proteins, including those with amino acid substitutions, alternative isoforms, post-translational modifications, and proteolytic cleavage products. The...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $472,073 Project Grant to The Trustees of Columbia University in the City of New York on September 1, 2025. This 5-year project aims to investigate the role of tau-induced changes in sumoylation and succinylation, two post-translational modifications, in the mitochondrial-nuclear communication and signaling that contributes to frontotemporal dementia (FTD) pathology. The research...
This federal Project Grant award of $431,750.00 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to Case Western Reserve University. The grant supports research to investigate the role of the CHCHD10 protein in regulating mitochondrial function and its potential impact on tau pathology in Alzheimer's disease (AD) and related dementias. The key objectives are to: 1) validate and extend CHCHD10's role in tau pathology in vivo and ex vivo, and 2) identify proteomics and transcriptomics signatures in CHCHD10-transduced human neurons derived from AD patients and assess post-translational modifications on tau protein altered by CHCHD10 in a mouse model. This research aims to provide insights into CHCHD10-associated mechanisms in tauopathy in AD and facilitate the therapeutic potential of increasing CHCHD10 expression as a strategy for treating these neurodegenerative disorders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $431.8k | 12/29/25 |